Advertisement

Topics

Roche's Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients

05:54 EDT 14 Jun 2018 | Pharmafile

Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), showing that the therapy could provide a range of “meaningful disability benefits” to multiple sclerosis patients.

read more

Original Article: Roche's Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients

NEXT ARTICLE

More From BioPortfolio on "Roche's Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...